The startup develops and manufactures pharmaceutical-grade extended-release buprenorphine specifically for laboratory mice and rats, ensuring compliance with cGMP standards. This formulation effectively controls post-procedural pain, addressing the critical need for reliable pain management solutions in veterinary care.
Funding
$6.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Laboratory animals undergoing surgical procedures often experience post-operative pain, which, if not adequately managed, can compromise their well-being and introduce variability into research results. Current pain management protocols may require frequent injections, leading to increased stress for the animals and additional workload for veterinary staff.
Solution
Fidelis Animal Health provides Ethiqa XR, a pharmaceutical-grade, extended-release buprenorphine formulation designed for post-procedural pain management in laboratory animals. Ethiqa XR utilizes a proprietary extended-release technology (Fidelipid LAI) to deliver sustained analgesia for up to 72 hours with a single subcutaneous injection. This reduces the need for frequent handling and minimizes stress in captive rodents, ferrets, laboratory rabbits, and non-human primates. The product is manufactured in compliance with current Good Manufacturing Practices (cGMP), ensuring purity, consistency, and the absence of endotoxins or polymers that could interfere with efficacy or cause adverse effects. By providing long-lasting pain relief, Ethiqa XR supports animal welfare and helps to ensure the integrity of research outcomes.
Target Audience
The primary customers are veterinary professionals, research institutions, and laboratory animal facilities focused on maintaining high standards of animal welfare and minimizing variability in research data.
Features
- Extended-release buprenorphine formulation providing up to 72 hours of post-procedural pain control
- Utilizes Fidelipid LAI technology for sustained drug delivery
- cGMP compliant manufacturing process ensures pharmaceutical-grade quality
- Reduces animal handling and stress with fewer injections
- FDA-indexed for use in captive rodents, ferrets, laboratory rabbits, and non-human primates
- Absence of endotoxins, polymers, and additives minimizes potential interference with research results
- Supports compliance with ethical guidelines and oversight agency directives regarding animal welfare